Vertex’s 22% Sales Growth And Pipeline Gives Biotech Something To Smile About

Sickle Cell Therapy Could Be Next Blockbuster

 
• By Andrew McConaghie

In a gloomy start to the year for the biotech sector, Vertex’s strong showing in cystic fibrosis and promising pipeline could lift the mood.

Vertex HQ, Boston
Vertex's full year results exceeded expectations, and could help revive flagging faith in biotech stocks. • Source: Getty Images

More from Business

More from Scrip